Logo

Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar- aflibercept) in Korea

Share this

Alteogen Reports Completion of P-I Study of ALT-L9 (biosimilar- aflibercept) in Korea

Shots:

  • The company has completed a P-I trial that assessed ALT-L9 vs Eylea in 28 patients in a ratio (1:1) with neovascular (wet) AMD. The trial was conducted at 4 major hospitals in Korea
  • The safety & efficacy of ALT-L9 were similar to Eylea and the results showed similar improvement effects in BCVA and CST. The P-I results will support the design of the P-III study and provide a path to a shorter P-III trial
  • Alteogen strengthens the competitiveness through global formulation and patents registration in the US- EU and Japan and filing of a process patent for PCT application

 ­ Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions